Tag: Cancer: Uterine
Pembrolizumab Aids Survival With High-Risk Endometrial Cancer
Findings seen in combination with chemotherapy following surgery in patients with curative intent
Sacituzumab Govitecan Shows Promise in Advanced Endometrial Cancer
Study reveals objective response rate of 22 percent and clinical benefit rate of 32 percent
Transvaginal Ultrasound Triage Strategy for Endometrial Cancer Not Reliable for Black Women at Risk
Significant proportion of those with EC have endometrial thickness below the range of diagnostic threshold for detection on ultrasound
FDA Approves KEYTRUDA + Chemo for Primary Advanced, Recurrent Endometrial Carcinoma
Significant reductions in disease progression or death seen with both mismatch repair-proficient and -deficient cases
Moderate, Heavy Use of Chemical Hair Relaxer Linked to Uterine Cancer
Among postmenopausal women, moderate and heavy use associated with increased risk versus never/light use
Selinexor Increases PFS for Endometrial Cancer With TP53 Mutations
Findings seen for maintenance therapy in patients with advanced or recurrent disease following response to systemic therapy
Rates of Endometrial Cancer Vary for U.S., Caribbean Black Women
Caribbean Black women have lowest rates of endometrioid and nonendometrioid subtypes
Adding Dostarlimab Improves Progression-Free Survival in Endometrial Cancer
Dostarlimab plus carboplatin-paclitaxel linked to increased progression-free survival overall and in dMMR-MSI-H population
Adding Pembrolizumab to Chemo Improves Survival in Endometrial Cancer
Addition of pembrolizumab to paclitaxel plus carboplatin yields longer progression-free survival in advanced, recurrent disease
Acupuncture, Acupressure Beneficial in Gynecologic Cancer Surgery Setting
Improvement seen in severe pain, anxiety for treatment groups receiving preoperative touch/relaxation with or without intraoperative acupuncture
